Table 2.
Univariate and multivariate regression analysis, EFS and OS
| EFS |
OS |
|||||||
|---|---|---|---|---|---|---|---|---|
| Univariate analysis |
Multivariate analysis |
Univariate analysis |
Multivariate analysis |
|||||
| Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value | |
| Age, ≥65 y | 0.99 (0.65-1.5) | .97 | Not included | 1.32 (0.84-2.07) | .22 | Not included | ||
| Male | 1.1 (0.73-1.8) | .55 | Not included | 1.48 (0.93-2.41) | .08 | 1.35 (0.91-2.06) | .13 | |
| Light chain isotype λ (reference κ) | 1.86 (1.11-3.21) | .02 | 1.30 (0.64-2.68) | .46 | 0.80 (0.46-1.36) | .42 | Not included | |
| BMPCs of >20% | 1.03 (0.62-1.73) | .88 | Not included | 1.27 (0.74-2.12) | .36 | Not included | ||
| dFLC ≥18 mg/dL | 2.58 (1.67-4.01) | <.001 | 2.15 (1.18-3.96) | .01 | 1.35 (0.85-2.15) | .19 | 1.11 (0.75-1.67) | .59 |
| t(11;14) | 1.69 (1.03-2.77) | .03 | 1.94 (1.08-3.54) | .02 | 0.83 (0.48-1.42) | .50 | Not included | |
| Proteinuria ≥5 g/24 h | 0.94 (0.58-1.54) | .81 | Not included | 0.78 (0.45-1.31) | .35 | Not included | ||
| Mayo 2004 with European modification stage IIIA/IIIB | 3.17 (2.05-5.09) | <.001 | 3.29 (1.81-6.16) | <.001 | 5.71 (3.45-9.67) | <.001 | 4.29 (2.78-6.79) | <.001 |
| Dara-CyBorD (vs CyBorD) | 0.15 (0.08-0.27) | <.001 | 0.37 (0.2-0.53) | <.001 | 0.33 (0.20-0.54) | <.001 | 0.55 (0.33-0.86) | .01 |
P values <0.05 in bold indicate statistical significance.